[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Lawson Research Institute of St. Joseph's\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":132},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,80,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100645324","accelerated-itbs-for-ptsd-and-depression-100645324",false,"NCT07682207","Accelerated iTBS for PTSD and Depression","Accelerated Intermittent Theta Burst Stimulation for Depression in Post-Traumatic Stress Disorder: A Single-Arm, Open-Label Feasibility Study","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Current post-traumatic stress disorder (PTSD) and current major depressive disorder (MDD), confirmed by a structured diagnostic interview (e.g., MINI 6.0 using the PTSD and MDD modules).\n* Minimum symptom severity at baseline: HAMD-17 score ≥14 (moderate depression) and\u002For PCL-5 score ≥33 (probable PTSD).\n* On a stable pharmacologic and\u002For psychotherapeutic regimen for at least 4 weeks prior to baseline, and willing to maintain stability during the treatment phase, unless medically necessary.\n* Capacity to provide informed consent and comply with study procedures and visits at St. Joseph's Health Care, London\u002FParkwood Institute.\n* Sufficient English proficiency to complete consent and study assessments.\n\nExclusion Criteria:\n\n* Neurologic or device-related risks, including seizure history, traumatic brain injury with loss of consciousness greater than 5 minutes, major neurologic illness, or metal\u002Felectronic implants contraindicated for transcranial magnetic stimulation.\n* Psychiatric or substance-related risks, including current psychotic disorder, acute mania, diagnosis of Bipolar I or Bipolar II disorder, recent substance use disorder, or imminent suicide risk.\n* Medical or medication-related risks, including unstable severe illness, high-risk medications, hearing impairment, unwillingness to use ear protection, or prior non-response to an adequate course of theta burst stimulation for the current depression\u002FPTSD episode.\n* Enrollment in another interventional trial.\n* Inability to comply with the study schedule.","ALL","18 Years",{"count":19,"type":20},16,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this pilot clinical trial is to learn if a faster brain stimulation schedule is practical, safe, tolerable, and acceptable. This study looks at accelerated intermittent theta burst stimulation, or accelerated iTBS. This is a non-invasive type of magnetic brain stimulation. This study is for adults with post-traumatic stress disorder (PTSD) and major depressive disorder (MDD).\n\nThe main questions this study aims to answer are:\n\n1. Can participants complete six short brain stimulation sessions per day for five days?\n2. Is this treatment schedule safe and tolerable for participants?\n3. What changes occur in depression symptoms, PTSD symptoms, anxiety, quality of life, and brain activity over time?\n\nParticipants will:\n\n1. Complete health screening and baseline assessments.\n2. Receive six short sessions of magnetic brain stimulation per day for five days.\n3. Have their brain activity measured using an EEG recording.\n4. Return for a post-treatment assessment at Week 2 and follow-up visits at Week 5 and Week 12.",[26,27],"Post Traumatic Stress Disorder PTSD","Major Depressive Disorder (MDD)",[29,30,31,32,33,34,35,36,37,38,39],"PTSD","MDD","Depression","Feasibility study","Accelerated intermittent theta burst stimulation","iTBS","Theta burst stimulation","Transcranial magnetic stimulation","TMS","Brain stimulation","EEG","NOT_YET_RECRUITING","2026-06-26",{"date":43,"type":44},"2026-07-02","ACTUAL",{"date":46,"type":20},"2026-07",{"date":48,"type":20},"2027-09",{"name":50,"class":51},"Lawson Research Institute of St. Joseph's","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100644699","standard-versus-novel-rfa-for-chronic-knee-pain-in-osteoarthritis-100644699","NCT07674082","Standard Versus Novel RFA for Chronic Knee Pain in Osteoarthritis","A Prospective Pilot Study Comparing Standard and Novel Radiofrequency Ablation Protocols for Chronic Knee Pain in Osteoarthritis","Inclusion Criteria:\n\n1. Any patient with knee osteoarthritis receiving knee RFA.\n2. Stable pain medications for past 1 month.\n3. Able to speak English.\n\nExclusion Criteria:\n\n1. Scheduled for knee surgery within 6 months following RFA procedure.\n2. Participating in another study that the Principal Investigator or Co-Investigators deem will interfere with the interpretation of the results.",{"count":61,"type":20},24,[23],"Brief Summary\n\nThe goal of this pilot study is to evaluate the feasibility and safety of conducting a randomized comparison of two standard-of-care knee radiofrequency ablation (RFA) techniques in adults with chronic knee pain related to knee osteoarthritis.\n\nParticipants who are already scheduled to receive knee RFA as part of their standard clinical care will be randomized to receive either a standard 3-target (standard) RFA protocol or a 6-target (novel) RFA protocol. The main purpose of this pilot study is to determine whether a future larger randomized trial comparing these two RFA approaches is feasible and safe to conduct.\n\nParticipants will complete questionnaires about pain, knee function, and stiffness at baseline and at follow-up timepoints for up to 12 months after the RFA procedure. Preliminary pain relief outcomes will also be explored to help inform the design of a future definitive trial.\n\nParticipants already scheduled for a knee RFA procedure as part of their standard of care for pain related to knee osteoarthritis will answer online survey questions about their pain for up to 12 months.",[65],"Osteoarthritis, Knee",[67,68,69,70,71],"radiofrequency ablation","radiofrequency","needle insertion","knee pain","pain management","2026-06-23",{"date":74,"type":44},"2026-06-29",{"date":76,"type":20},"2026-07-20",{"date":78,"type":20},"2029-08-20",{"name":50,"class":51},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100625208","empowerspine-program-100625208","NCT07419646","EmpowerSpine Program","EmpowerSpine Program: A Multiphase Optimization Strategy Trial","Inclusion Criteria:\n\n* 18 years of age or older\n* Canadian residents\n* identify as sustaining an SCI\n* living in the community\n* pain intensity ≥3 on the numeric rating scale\n\nExclusion Criteria:\n\n* have pain intensity\\\u003C3;\n* present with severe mental health disorder requiring face-to-face therapy (e.g., severe suicide ideation, recent history of psychosis, mania)",{"count":88,"type":20},100,[23],"Chronic pain affects over 60% of individuals living with spinal cord injuries (SCI), significantly impairing their daily lives and overall well-being. Traditional treatments like medications often provide limited relief and come with unwanted side effects. Recognizing this gap, the EmpowerSpine program was co-developed as an innovative, online, multidisciplinary pain management solution tailored for individuals with SCI. EmpowerSpine equips participants with evidence-based tools, including education about pain biology, behavioural strategies to manage daily activities, and techniques to improve self-monitoring and resilience. Delivered through an accessible digital platform, the program is designed to overcome barriers such as limited mobility, high costs, and geographic constraints. In initial trials, EmpowerSpine demonstrated high levels of satisfaction and adherence among participants, with improvements in pain intensity, mental health, and quality of life.\n\nThe proposed research seeks to refine EmpowerSpine using the multiphase optimization strategy (MOST), a pragmatic research framework, to identify which components of the program (i.e. clinician guidance, peer support groups, follow-up booster sessions) yield the best outcomes. A randomized controlled trial involving 100 participants will evaluate the program's impact on self-efficacy, pain levels, and overall quality of life. This work aims to optimize EmpowerSpine for scalability, making it a sustainable and effective resource for individuals with SCI across Canada. By leveraging partnerships with patient organizations and healthcare providers, the research will ensure the program addresses real-world needs and is positioned for widespread implementation. EmpowerSpine has the potential to revolutionize how chronic pain is managed in the SCI community, offering a scalable model of care that combines technology, evidence-based practices, and patient-centered approaches to improve lives.",[92,93,94,95],"Internet Delivered Treatment","Spinal Cord Injury","Chronic Pain","Multidisciplinary Approach","2026-02-13",{"date":98,"type":44},"2026-02-19",{"date":100,"type":20},"2026-06-01",{"date":102,"type":20},"2027-10-01",{"name":50,"class":51},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":52},"100528085","pursuing-reduction-in-fatigue-after-covid-19-via-exercise-and-rehabilitation-prefacer-a-randomized-feasibility-trial-100528085","NCT06156176","Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial","PREFACER","Inclusion Criteria:\n\n* Adults of at least 18 years of age\n* Able to provide informed consent\n* Can speak and understand English\n* Documented history of SARS-CoV-2 infection (positive PCR\u002Fantigen test during acute illness or clinical diagnosis by physician during or after the acute illness)\n* Fatigue symptoms within 3 months of COVID-19 infection, lasting at least 2 months\n* Fatigue symptoms cannot be explained by an alternative diagnosis\n* Fatigue symptoms may be new onset following initial recovery from an acute COVID-19 infection or persist from the initial illness\n* Fatigue symptoms may have an episodic nature, fluctuate or relapse over time\n* Minimal functional capability: able to walk 10-15 minutes and be recovered within 30-60 minutes or without significant post-exertional malaise (PEM)\n* Has applicable technology to access Microsoft Teams and Webex (i.e., computer, laptop, tablet)\n\nExclusion Criteria:\n\n* Active SARS-CoV-2 infection\n* Pre-existing physical, cognitive, and\u002For mental health conditions that make exercise contraindicated, consent unattainable, or that cause symptoms similar to those seen in post COVID-19 (e.g., major neurocognitive disorder, schizophrenia, chronic fatigue syndrome) that could affect data\n* Inability to follow study procedures\n* Pregnant and\u002For breastfeeding\n* Received investigational agents as part of a separate study within 30 days of the screening visit\n* Has any type of metal bodily implant in head or heart (i.e., pins, plates, pacemakers)\n* Current participation in other studies related to COVID-19, exercise, and\u002For fatigue interventions OR participation within 30 days of the screening visit",{"count":112,"type":20},60,[23],"Long COVID is a complex condition that affects approximately 1.4 million Canadians following SARS-CoV-2 infection. Fatigue is the most common symptom of Long COVID. This feasibility trial will evaluate a new rehabilitation program called COVIDEx for treating fatigue after COVID-19, and compare its effectiveness to the standard treatment currently used. The experimental treatment group will receive an 8-week multi-modal rehabilitation program with two 50-minute sessions per week. 60 participants will be recruited, randomly assigned to the COVIDEx program or standard of care (SoC) and followed for 24 weeks.",[116,117,118,119,120,121,122],"Long-COVID","Long COVID-19","Post-COVID-19 Syndrome","Post-COVID Syndrome","Fatigue","Post COVID-19 Condition","Post-COVID Condition","RECRUITING","2025-07-29",{"date":126,"type":44},"2025-08-01",{"date":128,"type":44},"2025-04-01",{"date":130,"type":20},"2026-04-01",{"name":50,"class":51},""]